S&P 500
7,623.68
-39.75
-0.52%
Dow
52,215.16
-652.82
-1.23%
Nasdaq
25,955.34
-53.52
-0.21%
NYSE Composite
24,126.34
-149.19
-0.61%
Russell 2000
2,778.43
-5.59
-0.20%
VIX
19.70
+0.67
+3.52%
ZLAB · Zai Lab Limited American Depositary Shares
HONG KONG EXCHANGES AND CLEARING LTD - Real Time Price • USD
Zai Lab Ltd (ZLAB)
HONG KONG EXCHANGES AND CLEARING LTD
Biotechnology
$24.05
+2.01
(+9.12%)
● At close: October 23 at 4:00:00 PM EDT
DAY'S RANGE
$24.05
$22.24
$24.50
52-WEEK RANGE
$24.05
$12.31
$23.20
What's happening
- ZLAB is up 9.12% today, trading at $24.05. — Live quote
- It's trading within 3% of its 52-week high ($23.20). (Finnhub fundamentals)
- Volume today (162,687) is well below its 3-month average of 8,068,640. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.05 actual vs. $-0.07 estimated (+24.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 9
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ZLAB
+30.26%
vs S&P 500
+19.47%
1-YEAR RETURN
ZLAB
-17.46%
vs S&P 500
-17.82%
6-MONTH RETURN
ZLAB
-2.68%
3-MONTH RETURN
ZLAB
+10.92%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.05
Est. $-0.07
BEAT +24.0%
2026-04-26 (Q1 2026)
$-0.05
Est. $-0.05
MISS -4.4%
2026-01-26 (Q4 2025)
$-0.05
Est. $-0.07
BEAT +24.0%
2025-10-26 (Q3 2025)
$-0.03
Est. $-0.04
BEAT +32.4%
Valuation Measures & Ratios
Enterprise Value4$2.21B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)5.74
Price / Book73.46
EV4 / Revenue4.92
EV4 / EBITDA—
Profit Margin-41.86%
Operating Margin-58.74%
Return on Equity (ROE8)-27.43%
Return on Assets (ROA9)-16.72%
Avg Volume (3M)8,068,640
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $19.32B | $19.19B | $40.62B | $35.59B | $43.74B |
| P/E | -108.21 | -108.93 | -243.53 | -168.56 | -195.39 |
| Price/Sales | 44.72 | 44.40 | 93.42 | 84.88 | 110.34 |
| Price/Book | 31.82 | 28.98 | 53.45 | 44.95 | 53.95 |
| EV/Revenue | 43.86 | 43.38 | 92.24 | 83.55 | 108.87 |
| EV/EBITDA | -81.04 | -87.46 | -187.49 | — | — |
| ROE | -29.41% | -26.61% | -21.95% | -26.66% | -27.61% |
| ROA | -16.61% | -16.08% | -14.39% | -18.14% | -19.08% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,149,727
Change from Prior Settlement-12.35%
% of Float—
Days to Cover (Short Ratio)9.04
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-23; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -3.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -41.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -17.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ZLAB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $106.3M | $99.6M | $116.1M | $110.0M | $106.5M | $102.3M | $100.5M | $87.1M |
| Operating income | -$76.5M | -$69.4M | -$48.8M | -$54.9M | -$56.3M | -$67.9M | -$76.1M | -$70.3M |
| Net income | -$50.8M | -$51.0M | -$36.0M | -$40.7M | -$48.4M | -$41.7M | -$80.3M | -$53.5M |
| EPS (diluted) | $-0.05 | $-0.05 | $-0.03 | $-0.04 | $-0.04 | $-0.04 | $-0.08 | $-0.05 |
| EPS (basic) | $-0.05 | $-0.05 | $-0.03 | $-0.04 | $-0.04 | $-0.04 | $-0.08 | $-0.05 |
| Operating margin | -$72 | -$70 | -$42 | -$50 | -$53 | -$66 | -$76 | -$81 |
| Net margin | -$48 | -$51 | -$31 | -$37 | -$45 | -$41 | -$80 | -$61 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.07B | $1.10B | $1.17B | $1.16B | $1.16B | $1.17B | $1.19B | $985.3M |
| Total liabilities | $467.8M | $433.8M | $456.9M | $399.0M | $372.4M | $362.6M | $344.9M | $317.7M |
| Stockholders' equity | $607.0M | $662.0M | $715.5M | $759.9M | $791.7M | $810.8M | $840.9M | $667.7M |
| Total current assets | $914.0M | $944.7M | $1.02B | $1.03B | $1.03B | $1.04B | $1.05B | $860.5M |
| Total current liabilities | $428.6M | $393.0M | $416.2M | $359.8M | $331.5M | $319.8M | $299.4M | $286.3M |
| Cash & equivalents | $607.5M | $651.3M | $679.6M | $717.2M | $732.2M | $757.3M | $449.7M | $616.1M |
| Marketable securities (current) | $10.0M | $10.0M | $10.0M | $0 | $0 | $0 | $330.0M | $0 |
| Accounts receivable | $69.6M | $54.1M | $106.1M | $85.4M | $88.5M | $76.6M | $85.2M | $50.0M |
| Inventory | $90.9M | $86.0M | $74.7M | $67.1M | $61.7M | $53.1M | $39.9M | $39.5M |
| Marketable securities (non-current) | — | — | — | — | — | — | $3.1M | $3.2M |
| Property, plant & equipment | $46.4M | $47.1M | $47.4M | $48.9M | $50.2M | $49.7M | $48.0M | $50.8M |
| Intangible assets | $85.8M | $75.8M | $76.1M | $55.3M | $56.5M | $56.2M | $56.0M | $51.7M |
| Other non-current assets | $3.5M | $3.2M | $3.1M | $2.1M | $2.6M | $2.5M | $5.8M | — |
| Accounts payable | $136.7M | $126.2M | $141.6M | $99.7M | $107.4M | $103.0M | $100.9M | $120.7M |
| Short-term debt | $238.1M | $213.8M | $204.5M | $203.0M | $174.5M | $173.4M | $131.7M | $113.0M |
| Other current liabilities | $48.8M | $47.0M | $63.7M | $51.5M | $44.1M | $36.8M | $58.7M | $46.1M |
| Other non-current liabilities | $225.0K | $40.0K | $0 | $325.0K | $325.0K | $325.0K | $325.0K | $325.0K |
| Common stock & paid-in capital | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $6.0K |
| Retained earnings | -$2.73B | -$2.68B | -$2.63B | -$2.58B | -$2.54B | -$2.50B | -$2.45B | -$2.37B |
| Accumulated other comprehensive income (loss) | $214.0K | $15.1M | $29.7M | $39.6M | $46.3M | $49.3M | $50.5M | $28.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$63.4M | -$11.9M | -$26.0M | -$32.0M | -$31.0M | -$61.7M | -$55.8M | -$26.8M |
| Investing cash flow | -$1.4M | -$22.3M | -$11.3M | -$4.0M | -$2.9M | $326.1M | -$347.8M | -$29.9M |
| Financing cash flow | $18.7M | $5.6M | -$430.0K | $20.8M | $8.8M | $43.1M | $237.8M | $42.2M |
| Free cash flow | -$64.7M | -$13.1M | -$26.7M | -$35.0M | -$33.9M | -$63.2M | -$58.4M | -$28.2M |
| Capital expenditures | $1.3M | $1.2M | $677.0K | $3.0M | $2.9M | $1.5M | $2.6M | $1.3M |
| Depreciation & amortization | $4.2M | $3.9M | $3.9M | $3.9M | $3.7M | $3.5M | $3.0M | $2.9M |
| Share-based compensation | $11.9M | $13.5M | $15.9M | $16.9M | $17.0M | $15.8M | $17.2M | $16.8M |
| Change in accounts receivable | $14.2M | -$53.3M | $19.7M | -$3.7M | $11.7M | -$8.7M | $36.7M | -$20.6M |
| Change in inventory | $10.6M | $11.2M | $18.9M | $6.0M | $8.9M | $13.2M | $507.0K | -$2.4M |
| Change in accounts payable | -$1.4M | $4.3M | $20.4M | -$6.9M | $3.8M | $2.7M | -$8.8M | $12.7M |
| Tax withholding on stock comp | $2.2M | $2.3M | $0 | $8.2M | $27.0K | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $460.2M | $399.0M | $266.7M | $215.0M | $144.3M |
| Operating income | -$229.4M | -$282.1M | -$366.6M | -$404.4M | -$700.1M |
| Net income | -$175.5M | -$257.1M | -$334.6M | -$443.3M | -$704.5M |
| EPS (diluted) | $-0.16 | $-0.26 | $-0.35 | $-0.46 | $-0.76 |
| EPS (basic) | $-0.16 | $-0.26 | $-0.35 | $-0.46 | $-0.76 |
| Operating margin | -$50 | -$71 | -$137 | -$188 | -$485 |
| Net margin | -$38 | -$64 | -$125 | -$206 | -$488 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.17B | $1.19B | $1.04B | $1.22B | $1.61B |
| Total liabilities | $456.9M | $344.9M | $240.2M | $174.5M | $230.0M |
| Stockholders' equity | $715.5M | $840.9M | $796.1M | $1.05B | $1.38B |
| Total current assets | $1.02B | $1.05B | $939.6M | $1.12B | $1.50B |
| Total current liabilities | $416.2M | $299.4M | $203.1M | $139.8M | $192.9M |
| Cash & equivalents | $679.6M | $449.7M | $790.2M | $1.01B | $964.1M |
| Marketable securities (current) | $10.0M | $330.0M | $16.3M | $0 | $445.0M |
| Accounts receivable | $106.1M | $85.2M | $59.2M | $40.0M | $47.5M |
| Inventory | $74.7M | $39.9M | $44.8M | $31.6M | $19.0M |
| Marketable securities (non-current) | — | $3.1M | $9.2M | $6.4M | $15.6M |
| Property, plant & equipment | $47.4M | $48.0M | $53.7M | $57.9M | $43.1M |
| Intangible assets | $76.1M | $56.0M | $13.4M | $1.5M | $1.8M |
| Other non-current assets | $3.1M | $5.8M | — | — | — |
| Accounts payable | $141.6M | $100.9M | $113.0M | $66.0M | $126.2M |
| Short-term debt | $204.5M | $131.7M | $0 | — | — |
| Other current liabilities | $63.7M | $58.7M | $83.0M | $66.8M | $60.8M |
| Other non-current liabilities | $0 | $325.0K | $325.0K | $0 | — |
| Common stock & paid-in capital | $7.0K | $7.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$2.63B | -$2.45B | -$2.20B | -$1.86B | -$1.42B |
| Accumulated other comprehensive income (loss) | $29.7M | $50.5M | $37.6M | $25.7M | -$23.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$150.8M | -$214.9M | -$198.2M | -$367.6M | -$549.2M |
| Investing cash flow | $307.9M | -$375.2M | -$10.8M | $420.0M | $250.0M |
| Financing cash flow | $72.4M | $349.9M | -$6.4M | -$1.7M | $820.2M |
| Free cash flow | -$158.9M | -$220.5M | -$205.4M | -$392.2M | -$567.5M |
| Capital expenditures | $8.1M | $5.7M | $7.2M | $24.6M | $18.3M |
| Depreciation & amortization | $15.0M | $11.9M | $9.0M | $8.2M | $6.5M |
| Share-based compensation | $65.6M | $70.7M | $79.6M | $61.3M | $40.7M |
| Change in accounts receivable | $18.9M | $27.0M | $20.0M | -$4.3M | $42.3M |
| Change in inventory | $47.0M | -$3.9M | $14.9M | $15.4M | $7.2M |
| Change in accounts payable | $19.9M | -$2.2M | $36.8M | -$53.8M | $63.5M |
| Tax withholding on stock comp | $8.2M | $0 | $8.8M | $7.6M | $4.3M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ZLAB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-14 to 2026-10-01
Recent transactions
- Insiders have net sold 156,142 shares over the last 182 days, across 1 purchase and 11 sales.
- Most recent: Chen Yajing (Chief Financial Officer) — Option exercise of 920 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)1,736 sh(1 txns)
Sales (open market)157,878 sh(11 txns)
Net Shares-156,142
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Chen Yajing | Chief Financial Officer | Option exercise | 2026-10-01 | 920 |
| Lis William | Reporting person | Open market sale | 2026-08-12 | 8,506 |
| Du Ying | Chairperson & CEO | Option exercise | 2026-07-02 | 11,048 |
| GAYNOR RICHARD | Reporting person | Open market purchase | 2026-07-01 | 1,736 |
| Edmondson Frazor Titus III | Chief Legal Officer | Open market sale | 2026-06-26 | 4,103 |
| Morrison Scott W | Reporting person | Grant / award | 2026-06-17 | 22,371 |
| Vounatsos Michel | Reporting person | Grant / award | 2026-06-17 | 22,371 |
| WIRTH PETER | Reporting person | Grant / award | 2026-06-17 | 22,371 |
| DIEKMAN JOHN D | Reporting person | Grant / award | 2026-06-17 | 22,371 |
| Leung Nisa | Reporting person | Grant / award | 2026-06-17 | 22,371 |
| MOULDER LEON O JR | Reporting person | Grant / award | 2026-06-17 | 22,371 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Chen Yajing | Chief Financial Officer | Option exercise | 920 | — |
| 2026-10-01 | Chen Yajing | Chief Financial Officer | Tax withholding | 315 | $25.50 |
| 2026-08-19 | Chen Yajing | Chief Financial Officer | Open market sale | 260 | $27.00 |
| 2026-08-14 | Chen Yajing | Chief Financial Officer | Option exercise | 1,250 | — |
| 2026-08-14 | Chen Yajing | Chief Financial Officer | Tax withholding | 427 | $25.90 |
| 2026-08-12 | Lis William | Reporting person | Open market sale | 8,506 | $25.00 |
| 2026-08-11 | Chen Yajing | Chief Financial Officer | Open market sale | 619 | $25.00 |
| 2026-07-02 | Du Ying | Chairperson & CEO | Option exercise | 11,048 | — |
| 2026-07-02 | Du Ying | Chairperson & CEO | Tax withholding | 4,348 | $19.12 |
| 2026-07-01 | GAYNOR RICHARD | Reporting person | Open market purchase | 1,736 | $19.05 |
| 2026-07-01 | Du Ying | Chairperson & CEO | Option exercise | 18,000 | — |
| 2026-07-01 | Du Ying | Chairperson & CEO | Tax withholding | 7,083 | $19.15 |
| 2026-06-30 | Du Ying | Chairperson & CEO | Open market sale | 7,026 | $18.53 |
| 2026-06-29 | Du Ying | Chairperson & CEO | Option exercise | 17,970 | — |
| 2026-06-26 | Edmondson Frazor Titus III | Chief Legal Officer | Open market sale | 4,103 | $17.46 |
| 2026-06-26 | Du Ying | Chairperson & CEO | Open market sale | 24,543 | $17.46 |
| 2026-06-26 | Chen Yajing | Chief Financial Officer | Open market sale | 2,264 | $17.46 |
| 2026-06-25 | Edmondson Frazor Titus III | Chief Legal Officer | Option exercise | 14,600 | — |
| 2026-06-25 | Du Ying | Chairperson & CEO | Option exercise | 58,800 | — |
| 2026-06-25 | Chen Yajing | Chief Financial Officer | Option exercise | 6,250 | — |
| 2026-06-22 | Lis William | Reporting person | Open market sale | 7,040 | $18.09 |
| 2026-06-17 | GAYNOR RICHARD | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-06-17 | Morrison Scott W | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-06-17 | Lis William | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-06-17 | Vounatsos Michel | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-06-17 | WIRTH PETER | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-06-17 | DIEKMAN JOHN D | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-06-17 | Leung Nisa | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-06-17 | MOULDER LEON O JR | Reporting person | Grant / award | 22,371 | $0.00 |
| 2026-05-27 | Du Ying | Chairperson & CEO | Gift | 33,993 | $0.00 |
| 2026-05-27 | Du Ying | Chairperson & CEO | Gift | 53,850 | $0.00 |
| 2026-05-26 | Du Ying | Chairperson & CEO | Gift | 19,857 | $0.00 |
| 2026-05-19 | Du Ying | Chairperson & CEO | Option exercise | 261,092 | $1.74 |
| 2026-05-19 | Du Ying | Chairperson & CEO | Tax withholding | 117,435 | $18.75 |
| 2026-05-18 | Du Ying | Chairperson & CEO | Option exercise | 50,000 | $1.74 |
| 2026-05-18 | Du Ying | Chairperson & CEO | Open market sale | 50,000 | $19.00 |
| 2026-05-15 | Du Ying | Chairperson & CEO | Option exercise | 50,000 | $1.74 |
| 2026-05-15 | Du Ying | Chairperson & CEO | Open market sale | 50,000 | $20.74 |
| 2026-05-14 | Edmondson Frazor Titus III | Chief Legal Officer | Open market sale | 3,517 | $20.19 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-23 19:21 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-23 | 8-K | 2026-10-22 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
Recent news
Headlines about ZLAB (Zai Lab Limited American Depositary Shares). Links open the publisher — we don’t host full articles.
-
Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer Transcript
Seeking Alpha · 2026-10-23 -
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
Yahoo Finance · 2026-10-23 -
Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study
Yahoo Finance · 2026-10-23 -
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Yahoo · 2026-10-23 -
Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial
Yahoo · 2026-10-23 -
At $22.04 per depositary share, Zai Lab (ZLAB) agrees to sell stock to fund drug development.
Stock Titan · 2026-10-23 -
Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3
Benzinga · 2026-10-23 -
Zai Lab announces $250M private placement
Seeking Alpha · 2026-10-23
No headlines in this category right now — try “All”.